Targeted failure of the week. Kadcyla. When rocket science medicine fails...

Oct 22 (Reuters) - ImmunoGen Inc said the gastric cancer drug it is developing with Roche Holding AG did not meet the main goal in a large study. http://finance.yahoo.com/news/immunogen-roche-gastric-cancer-drug-121659032.html

Trastuzumab emtansine ( ado-trastuzumab emtansine, trade name Kadcyla) is an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent DM1.

 

This drug is a real rocket science approach. And it failed...